Fiorino Gionata, Bent-Ennakhil Nawal, Varriale Pasquale, Braegger Fiona, Hoefkens Eveline
Department of Gastroenterology and Digestive Endoscopy, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy.
Gastroenterology and Digestive Endoscopy, San Camillo-Forlanini Hospital, Rome, Italy.
Inflamm Bowel Dis. 2024 Dec 5;30(12):2380-2394. doi: 10.1093/ibd/izae015.
Inflammatory bowel disease requires long-term treatment; therefore, understanding patient preferences is important in aiding informed treatment decision making. This study explored patients' preferences for treatment attributes of available inflammatory bowel disease therapies.
Adult patients from 7 European countries who self-reported previous/current treatment for Crohn's disease (CD) or ulcerative colitis (UC) participated in an online survey via the Carenity platform. In a discrete choice experiment, the relative importance of treatment attributes for CD and UC was estimated using conditional logit models. Latent class analysis was conducted to estimate heterogeneous treatment preferences based on patient profiles. Patients' perspectives and preferences regarding their quality of life were assessed.
Across 686 completed survey responses (CD, n = 360; UC, n = 326), the mean patient age was 48 and 50 years, respectively. Patients with CD ranked route of administration as the most important attribute (attribute importance: 32%), preferring subcutaneous over intravenous treatment (P < .001). Patients with UC ranked route of administration and frequency of serious adverse events as the most important attributes (attribute importance: 31% and 23%, respectively), preferring oral (P < .001) and subcutaneous (P < .001) over intravenous treatment and treatment that minimized the risk of serious adverse events (P < .001) or mild adverse events (P < .01). Latent class analyses confirmed the impact of patients' sociodemographic profile on their preferences. All patients prioritized general well-being, energy level, and daily activities as the most important aspects for improvement through treatment.
Patient preferences for treatment attributes varied among patients with CD or UC, highlighting the importance of personalized care and shared decision making to maximize treatment benefits.
炎症性肠病需要长期治疗；因此，了解患者偏好对于帮助做出明智的治疗决策很重要。本研究探讨了患者对现有炎症性肠病治疗方法的治疗属性的偏好。
来自7个欧洲国家的成年患者，他们自我报告曾接受过/正在接受克罗恩病（CD）或溃疡性结肠炎（UC）的治疗，通过Carenity平台参与了一项在线调查。在一项离散选择实验中，使用条件logit模型估计CD和UC治疗属性的相对重要性。进行潜在类别分析以根据患者特征估计异质性治疗偏好。评估了患者对其生活质量的看法和偏好。
在686份完整的调查回复中（CD患者360例，UC患者326例），患者的平均年龄分别为48岁和50岁。CD患者将给药途径列为最重要的属性（属性重要性：32%），比起静脉治疗更喜欢皮下治疗（P <.001）。UC患者将给药途径和严重不良事件的发生频率列为最重要的属性（属性重要性分别为31%和23%），比起静脉治疗以及使严重不良事件（P <.001）或轻度不良事件风险最小化的治疗（P <.01），更喜欢口服（P <.001）和皮下治疗（P <.001）。潜在类别分析证实了患者社会人口统计学特征对其偏好的影响。所有患者都将总体幸福感、精力水平和日常活动列为通过治疗改善的最重要方面。
CD或UC患者对治疗属性的偏好各不相同，这突出了个性化护理和共同决策以最大化治疗益处的重要性。
Zotero 插件
